Selinexor 40 mg

DRUG3 trials

Conditions

Colorectal Cancer (CRC)Mild ThrombocytopeniaModerate ThrombocytopeniaMultiple Myeloma in RelapseMultiple Myeloma, RefractoryMyelofibrosisNon-Small Cell Lung Carcinoma (NSCLC)Other Solid Tumors

Phase 1

Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment

CompletedNCT04256707

Karyopharm Therapeutics IncColorectal Cancer (CRC), Non-Small Cell Lung Carcinoma (NSCLC), Other Solid Tumors

Start: 2020-01-14End: 2024-07-31Updated: 2025-03-19

Phase 2

A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

RecruitingNCT05980806

Karyopharm Therapeutics IncMild Thrombocytopenia, Moderate Thrombocytopenia, Myelofibrosis

Start: 2024-04-22End: 2028-10-01Target: 58Updated: 2026-02-12

HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM

RecruitingNCT06822972

Duke UniversityMultiple Myeloma in Relapse, Multiple Myeloma, Refractory

Start: 2025-08-22End: 2027-12-31Target: 27Updated: 2025-09-02

Journal of Clinical Oncology2024-06-011 citations

Open-label phase 1/2 study evaluating the tolerability and antitumor activity of selinexor and pembrolizumab in colorectal cancer.

Journal of Clinical Oncology2022-01-191 citations

Open-label phase 1 study evaluating the tolerability and anti-tumor activity of selinexor and pembrolizumab in colorectal cancer.

Journal of Clinical Oncology2021-05-202 citations

Selinexor 40 mg

Sponsors

Conditions

Phase 1

Phase 2

Related Papers